Correction to “Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studies Including Impact on Drug Interaction Risk Assessment”

the three pairs of summary rows ["Overall AFE (n)" and "% Within 2-fold (n)"] in Table 3 were accidentally duplicated.The corrected Table 3 is provided below.